Hospital shares fall again as India drug-pricing case moves on

what happened

Shares of Indian hospital operators came under renewed pressure on Monday, October 12, after the Supreme Court concluded a hearing on drug price caps, CNBC TV18 reported. Apollo Hospitals and Max Healthcare each declined as much as 3%. Fortis Healthcare dropped 3.3%, while Aster DM Quality Care lost 2.8%. Park Medi World, North India’s second-largest private hospital chain, fell as much as 6%.

The government told the court that pricing must be balanced with availability and said it did not seek to regulate the entire drug market because prices in the country are already the lowest globally. The Supreme Court questioned why the authorities could not oversee the whole market and said manufacturers may calculate prices using research and development costs, yet products can ultimately be sold at 10 times the MRP. The government said it was open to some of the court’s proposals.

The next hearing is scheduled for Tuesday, October 27. The court had previously described steep hospital markups on cancer medicines as “carnage” and proposed a uniform 16% margin for all drugs. The government later imposed a 30% trade-margin ceiling on all non-scheduled anti-cancer medicines. In 2019, NPPA had applied a 30% cap to 42 such drugs; the government said the move cut prices and generated about ₹984 crore in annual savings. Fortis ended down 3.5%, while Apollo, Max and Aster DM continued to trade 2% to 3% lower.

why it matters

The proceedings keep regulatory uncertainty elevated for private hospital operators, as changes to medicine margins could affect the economics of hospital pharmacies and treatment revenue.

instruments